Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04973306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Study acronym: iCROSS
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 30, 2022 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revised
    • Study description revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jul 2021 to Mar 2, 2022
    • Site details revised
    • Collaborators: 12 to 15
    • Study title shortened, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.
Trial Details
NCT Number NCT04973306
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Peking University Cancer Hospital & Institute, Shanghai Chest Hospital, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Zhongshan Hospital (Xiamen), Fudan University, Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Tongji Hospital, Sun Yat-sen University, Shanghai Fifth People's Hospital
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Related terms Esophageal Squamous Cell Carcinoma
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov